MicroRNA-200a Promotes Anoikis Resistance and Metastasis by Targeting YAP1 in Human Breast Cancer
Purpose: The process of metastases involves the dissociation of cells from the primary tumor, penetration into the basement membrane, invasion, and exiting from the vasculature to seed and colonize distant tissues. miR-200a is involved in this multistep metastatic cascade. This study aimed to test t...
Saved in:
Published in | Clinical cancer research Vol. 19; no. 6; pp. 1389 - 1399 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
15.03.2013
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Purpose: The process of metastases involves the dissociation of cells from the primary tumor, penetration into the basement membrane, invasion, and exiting from the vasculature to seed and colonize distant tissues. miR-200a is involved in this multistep metastatic cascade. This study aimed to test the hypothesis that miR-200a promotes metastasis through increased anoikis resistance in breast cancer.
Experimental Design: Breast cancer cells transfected with mimic or inhibitor for miR-200a were assayed for anoikis in vitro. miR-200a expression was assessed by quantitative real-time PCR (qRT-PCR). Luciferase assays, colony formation assays, and animal studies were conducted to identify the targets of miR-200a and the mechanism by which it promotes anoikis resistance.
Results: We found that overexpression of miR-200a promotes whereas inhibition of miR-200a suppresses anoikis resistance in breast cancer cells. We identified Yes-associated protein 1 (YAP1) as a novel target of miR-200a. Our data showed that targeting of YAP1 by miR-200a resulted in decreased expression of proapoptotic proteins, which leads to anoikis resistance. Overexpression of miR-200a protected tumor cells from anoikis and promoted metastases in vivo. Furthermore, knockdown of YAP1 phenocopied the effects of miR-200a overexpression, whereas restoration of YAP1 in miR-200a overexpressed breast cancer cells reversed the effects of miR-200a on anoikis and metastasis. Remarkably, we found that YAP1 expression was inversely correlated with miR-200a expression in breast cancer clinical specimens, and miR-200a expression was associated with distant metastasis in patients with breast cancer.
Conclusions: Our data suggest that miR-200a functions as anoikis suppressor and contributes to metastasis in breast cancer. Clin Cancer Res; 19(6); 1389–99. ©2013 AACR. |
---|---|
AbstractList | Purpose: The process of metastases involves the dissociation of cells from the primary tumor, penetration into the basement membrane, invasion, and exiting from the vasculature to seed and colonize distant tissues. miR-200a is involved in this multistep metastatic cascade. This study aimed to test the hypothesis that miR-200a promotes metastasis through increased anoikis resistance in breast cancer.
Experimental Design: Breast cancer cells transfected with mimic or inhibitor for miR-200a were assayed for anoikis in vitro. miR-200a expression was assessed by quantitative real-time PCR (qRT-PCR). Luciferase assays, colony formation assays, and animal studies were conducted to identify the targets of miR-200a and the mechanism by which it promotes anoikis resistance.
Results: We found that overexpression of miR-200a promotes whereas inhibition of miR-200a suppresses anoikis resistance in breast cancer cells. We identified Yes-associated protein 1 (YAP1) as a novel target of miR-200a. Our data showed that targeting of YAP1 by miR-200a resulted in decreased expression of proapoptotic proteins, which leads to anoikis resistance. Overexpression of miR-200a protected tumor cells from anoikis and promoted metastases in vivo. Furthermore, knockdown of YAP1 phenocopied the effects of miR-200a overexpression, whereas restoration of YAP1 in miR-200a overexpressed breast cancer cells reversed the effects of miR-200a on anoikis and metastasis. Remarkably, we found that YAP1 expression was inversely correlated with miR-200a expression in breast cancer clinical specimens, and miR-200a expression was associated with distant metastasis in patients with breast cancer.
Conclusions: Our data suggest that miR-200a functions as anoikis suppressor and contributes to metastasis in breast cancer. Clin Cancer Res; 19(6); 1389–99. ©2013 AACR. The process of metastases involves the dissociation of cells from the primary tumor, penetration into the basement membrane, invasion, and exiting from the vasculature to seed and colonize distant tissues. miR-200a is involved in this multistep metastatic cascade. This study aimed to test the hypothesis that miR-200a promotes metastasis through increased anoikis resistance in breast cancer.PURPOSEThe process of metastases involves the dissociation of cells from the primary tumor, penetration into the basement membrane, invasion, and exiting from the vasculature to seed and colonize distant tissues. miR-200a is involved in this multistep metastatic cascade. This study aimed to test the hypothesis that miR-200a promotes metastasis through increased anoikis resistance in breast cancer.Breast cancer cells transfected with mimic or inhibitor for miR-200a were assayed for anoikis in vitro. miR-200a expression was assessed by quantitative real-time PCR (qRT-PCR). Luciferase assays, colony formation assays, and animal studies were conducted to identify the targets of miR-200a and the mechanism by which it promotes anoikis resistance.EXPERIMENTAL DESIGNBreast cancer cells transfected with mimic or inhibitor for miR-200a were assayed for anoikis in vitro. miR-200a expression was assessed by quantitative real-time PCR (qRT-PCR). Luciferase assays, colony formation assays, and animal studies were conducted to identify the targets of miR-200a and the mechanism by which it promotes anoikis resistance.We found that overexpression of miR-200a promotes whereas inhibition of miR-200a suppresses anoikis resistance in breast cancer cells. We identified Yes-associated protein 1 (YAP1) as a novel target of miR-200a. Our data showed that targeting of YAP1 by miR-200a resulted in decreased expression of proapoptotic proteins, which leads to anoikis resistance. Overexpression of miR-200a protected tumor cells from anoikis and promoted metastases in vivo. Furthermore, knockdown of YAP1 phenocopied the effects of miR-200a overexpression, whereas restoration of YAP1 in miR-200a overexpressed breast cancer cells reversed the effects of miR-200a on anoikis and metastasis. Remarkably, we found that YAP1 expression was inversely correlated with miR-200a expression in breast cancer clinical specimens, and miR-200a expression was associated with distant metastasis in patients with breast cancer.RESULTSWe found that overexpression of miR-200a promotes whereas inhibition of miR-200a suppresses anoikis resistance in breast cancer cells. We identified Yes-associated protein 1 (YAP1) as a novel target of miR-200a. Our data showed that targeting of YAP1 by miR-200a resulted in decreased expression of proapoptotic proteins, which leads to anoikis resistance. Overexpression of miR-200a protected tumor cells from anoikis and promoted metastases in vivo. Furthermore, knockdown of YAP1 phenocopied the effects of miR-200a overexpression, whereas restoration of YAP1 in miR-200a overexpressed breast cancer cells reversed the effects of miR-200a on anoikis and metastasis. Remarkably, we found that YAP1 expression was inversely correlated with miR-200a expression in breast cancer clinical specimens, and miR-200a expression was associated with distant metastasis in patients with breast cancer.Our data suggest that miR-200a functions as anoikis suppressor and contributes to metastasis in breast cancer.CONCLUSIONSOur data suggest that miR-200a functions as anoikis suppressor and contributes to metastasis in breast cancer. The process of metastases involves the dissociation of cells from the primary tumor, penetration into the basement membrane, invasion, and exiting from the vasculature to seed and colonize distant tissues. miR-200a is involved in this multistep metastatic cascade. This study aimed to test the hypothesis that miR-200a promotes metastasis through increased anoikis resistance in breast cancer. Breast cancer cells transfected with mimic or inhibitor for miR-200a were assayed for anoikis in vitro. miR-200a expression was assessed by quantitative real-time PCR (qRT-PCR). Luciferase assays, colony formation assays, and animal studies were conducted to identify the targets of miR-200a and the mechanism by which it promotes anoikis resistance. We found that overexpression of miR-200a promotes whereas inhibition of miR-200a suppresses anoikis resistance in breast cancer cells. We identified Yes-associated protein 1 (YAP1) as a novel target of miR-200a. Our data showed that targeting of YAP1 by miR-200a resulted in decreased expression of proapoptotic proteins, which leads to anoikis resistance. Overexpression of miR-200a protected tumor cells from anoikis and promoted metastases in vivo. Furthermore, knockdown of YAP1 phenocopied the effects of miR-200a overexpression, whereas restoration of YAP1 in miR-200a overexpressed breast cancer cells reversed the effects of miR-200a on anoikis and metastasis. Remarkably, we found that YAP1 expression was inversely correlated with miR-200a expression in breast cancer clinical specimens, and miR-200a expression was associated with distant metastasis in patients with breast cancer. Our data suggest that miR-200a functions as anoikis suppressor and contributes to metastasis in breast cancer. |
Author | Shen, Zhen-Zhou Hu, Jing-Ying Song, Hou-Yan Di, Gen-Hong Luo, Jian-Min Shao, Zhi-Ming Kuang, Xia-Ying Wu, Jiong Yu, San-Jian Hou, Yi-Feng |
Author_xml | – sequence: 1 givenname: San-Jian surname: Yu fullname: Yu, San-Jian – sequence: 2 givenname: Jing-Ying surname: Hu fullname: Hu, Jing-Ying – sequence: 3 givenname: Xia-Ying surname: Kuang fullname: Kuang, Xia-Ying – sequence: 4 givenname: Jian-Min surname: Luo fullname: Luo, Jian-Min – sequence: 5 givenname: Yi-Feng surname: Hou fullname: Hou, Yi-Feng – sequence: 6 givenname: Gen-Hong surname: Di fullname: Di, Gen-Hong – sequence: 7 givenname: Jiong surname: Wu fullname: Wu, Jiong – sequence: 8 givenname: Zhen-Zhou surname: Shen fullname: Shen, Zhen-Zhou – sequence: 9 givenname: Hou-Yan surname: Song fullname: Song, Hou-Yan – sequence: 10 givenname: Zhi-Ming surname: Shao fullname: Shao, Zhi-Ming |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23340296$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kUtPxCAUhYnROI76EzQs3XQECqWNq9r4SnxlMi5cEUrpBG2pAl3476WZmY0LV1xuvnNv7jlzsG8HqwE4w2iBMcsvMeJ5gmhKFlW1TDBJcMGKPXCEGeNJSjK2H-sdMwNz7z8QwhQjeghmJE0pIkV2BOSTUW5YPpcJQUjCVzf0Q9AelnYwn8bDpfbGB2mVhtI28EkHGb-xB-sfuJJurYOxa_hevmJoLLwfe2nhtdORgtUkcyfgoJWd16fb9xi83d6sqvvk8eXuoSofE5VyFhKeZYjUDCvect5KRZsm10qqTKmsqTnNOMsp12lLdUuKppCE1Vw2Kp7HMp7z9BhcbOZ-ueF71D6I3nilu05aPYxe4BTznCFEcUTPt-hY97oRX8700v2InS0RuNoA0RvvnW6FMkEGM9jgpOkERmIKQUwGi8lgEUMQmIgphKhmf9S7Bf_rfgE5m4kg |
CitedBy_id | crossref_primary_10_18632_oncotarget_20155 crossref_primary_10_1016_j_canlet_2017_04_011 crossref_primary_10_1016_j_canlet_2014_08_036 crossref_primary_10_1371_journal_pone_0309289 crossref_primary_10_2174_1574892814666181231142136 crossref_primary_10_3892_etm_2018_6895 crossref_primary_10_1038_s41598_024_73632_0 crossref_primary_10_18632_oncotarget_16577 crossref_primary_10_18632_oncotarget_21913 crossref_primary_10_1016_j_celrep_2018_10_001 crossref_primary_10_1111_cpr_12527 crossref_primary_10_3389_fgene_2023_1134779 crossref_primary_10_1002_jcp_29040 crossref_primary_10_1016_j_bbamcr_2013_06_026 crossref_primary_10_1007_s00404_022_06442_2 crossref_primary_10_1016_j_lfs_2020_118303 crossref_primary_10_1016_j_pharmthera_2017_12_011 crossref_primary_10_3892_or_2017_5600 crossref_primary_10_1016_j_ccell_2014_11_025 crossref_primary_10_1038_nrc3789 crossref_primary_10_1038_emm_2017_33 crossref_primary_10_1016_j_canlet_2017_04_032 crossref_primary_10_1016_j_jacbts_2024_02_019 crossref_primary_10_3390_cancers13236020 crossref_primary_10_1248_bpb_b19_00795 crossref_primary_10_1038_s41418_017_0012_4 crossref_primary_10_1186_s12935_021_01999_5 crossref_primary_10_1038_s41388_020_1166_y crossref_primary_10_3390_genes14051075 crossref_primary_10_3390_cancers12051225 crossref_primary_10_4048_jbc_2019_22_e19 crossref_primary_10_1134_S1022795418070086 crossref_primary_10_1177_00220345241242047 crossref_primary_10_3892_ol_2013_1593 crossref_primary_10_1016_j_lfs_2023_121980 crossref_primary_10_1007_s11010_024_05199_3 crossref_primary_10_1016_j_jhep_2015_01_039 crossref_primary_10_1016_j_humpath_2017_08_032 crossref_primary_10_18632_oncotarget_3052 crossref_primary_10_7717_peerj_10397 crossref_primary_10_1016_j_prp_2018_04_010 crossref_primary_10_1186_1476_4598_13_256 crossref_primary_10_1002_mco2_718 crossref_primary_10_1007_s11033_021_06666_6 crossref_primary_10_3390_cancers10040115 crossref_primary_10_1038_s41598_021_82431_w crossref_primary_10_1038_s41598_023_51124_x crossref_primary_10_1186_s12885_022_10118_0 crossref_primary_10_3390_cancers14205121 crossref_primary_10_1016_j_biopha_2017_06_055 crossref_primary_10_1007_s11010_022_04384_6 crossref_primary_10_1016_j_bbcan_2014_02_002 crossref_primary_10_3390_biom12060781 crossref_primary_10_1038_s41388_021_02000_3 crossref_primary_10_4251_wjgo_v15_i6_988 crossref_primary_10_3389_fonc_2018_00580 crossref_primary_10_1002_gcc_22422 crossref_primary_10_1038_s41598_021_89855_4 crossref_primary_10_1038_s41598_021_89288_z crossref_primary_10_1007_s13277_014_2202_8 crossref_primary_10_1016_j_prp_2021_153405 crossref_primary_10_1186_s12885_017_3930_0 crossref_primary_10_1371_journal_pone_0135119 crossref_primary_10_1172_JCI75695 crossref_primary_10_1016_j_ygyno_2014_01_047 crossref_primary_10_1002_cbf_3119 crossref_primary_10_3892_or_2015_4168 crossref_primary_10_3390_cancers13123100 crossref_primary_10_1177_1533033819828709 crossref_primary_10_2217_fon_2020_1080 crossref_primary_10_1007_s12094_015_1353_4 crossref_primary_10_1017_erm_2015_12 crossref_primary_10_3389_fonc_2021_708765 crossref_primary_10_1016_j_hjc_2020_10_006 crossref_primary_10_1074_jbc_RA118_004251 crossref_primary_10_3389_fonc_2023_1226118 crossref_primary_10_1002_adbi_202300532 crossref_primary_10_1007_s11596_018_1872_7 crossref_primary_10_1021_acs_biochem_5b01014 crossref_primary_10_1007_s12282_025_01666_x crossref_primary_10_1016_j_drup_2024_101099 crossref_primary_10_3389_fphar_2016_00271 crossref_primary_10_1186_s12935_021_02408_7 crossref_primary_10_1080_2162402X_2016_1160187 crossref_primary_10_1111_jog_13027 crossref_primary_10_1155_2018_4039173 crossref_primary_10_1080_10641955_2020_1757700 crossref_primary_10_1093_carcin_bgu202 crossref_primary_10_1038_s41598_021_82286_1 crossref_primary_10_1016_j_mam_2019_09_005 crossref_primary_10_1186_s13046_016_0338_7 crossref_primary_10_1016_j_ejca_2016_11_004 crossref_primary_10_3390_biology10040307 crossref_primary_10_4161_rna_26541 crossref_primary_10_3390_cells9081790 crossref_primary_10_1007_s12094_015_1364_1 crossref_primary_10_3390_ijms23179535 crossref_primary_10_1016_j_canlet_2024_216672 crossref_primary_10_1155_2018_2754941 crossref_primary_10_1016_j_isci_2024_110638 crossref_primary_10_1371_journal_pone_0159686 crossref_primary_10_3748_wjg_v21_i11_3245 crossref_primary_10_1016_j_canlet_2021_04_025 crossref_primary_10_1016_j_critrevonc_2015_12_004 crossref_primary_10_1161_ATVBAHA_115_305748 crossref_primary_10_1007_s11010_022_04353_z crossref_primary_10_1159_000507538 crossref_primary_10_3390_cancers14143386 crossref_primary_10_1007_s10555_013_9463_3 crossref_primary_10_1186_s12964_023_01183_4 crossref_primary_10_3390_pharmaceutics12121193 crossref_primary_10_1038_srep11567 crossref_primary_10_1016_j_cellsig_2019_109460 crossref_primary_10_1016_j_yexcr_2018_04_024 crossref_primary_10_1371_journal_pone_0206644 crossref_primary_10_3389_fgene_2019_00180 |
Cites_doi | 10.1016/j.molcel.2010.05.018 10.1038/nprot.2010.150 10.1158/0008-5472.CAN-05-1150 10.1016/j.bcp.2008.07.023 10.4161/cc.10.21.17921 10.1016/S1097-2765(02)00776-1 10.1093/nar/gkm995 10.1074/jbc.M010484200 10.1038/sj.cdd.4402063 10.1074/jbc.C800074200 10.1093/nar/gkr1048 10.1038/nm.2401 10.1016/j.canlet.2008.05.029 10.1155/2010/821717 10.1158/0008-5472.CAN-09-2111 10.1016/j.cell.2011.02.013 10.1038/ncb1722 10.1158/1078-0432.CCR-07-1731 10.1016/j.cell.2009.03.047 10.1016/j.molcel.2007.08.008 10.1038/nature06174 10.1038/nature06487 10.1016/j.cell.2009.07.011 10.1016/j.cell.2005.06.007 10.1074/jbc.M804380200 10.1016/j.molcel.2007.06.017 10.1158/0008-5472.CAN-08-1942 10.1016/j.molcel.2007.12.022 10.1038/nrc1670 10.1126/science.1203543 10.1101/gad.1640608 10.1056/NEJMoa050518 10.1016/j.molcel.2010.08.013 10.1038/cdd.2008.108 10.1016/S0140-6736(07)60781-8 10.1038/embor.2008.74 10.1371/journal.pone.0007181 10.1093/nar/gkp292 10.1371/journal.pbio.0020363 10.1093/bioinformatics/btq675 10.1016/j.ygyno.2009.05.022 |
ContentType | Journal Article |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1158/1078-0432.CCR-12-1959 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | CrossRef MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1557-3265 |
EndPage | 1399 |
ExternalDocumentID | 23340296 10_1158_1078_0432_CCR_12_1959 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- 18M 29B 2FS 2WC 34G 39C 53G 5GY 5RE 5VS 6J9 AAFWJ AAJMC AAYXX ABOCM ACGFO ACIWK ACPRK ACSVP ADBBV ADCOW ADNWM AENEX AFHIN AFOSN AFRAH AFUMD ALMA_UNASSIGNED_HOLDINGS BAWUL BR6 BTFSW CITATION CS3 DIK DU5 E3Z EBS EJD F5P FRP GX1 H13 IH2 KQ8 L7B LSO OK1 P0W P2P QTD RCR RHI RNS SJN TR2 UDS W2D W8F WOQ YKV CGR CUY CVF ECM EIF NPM 7X8 |
ID | FETCH-LOGICAL-c375t-76602b51c7f77fac4dd8ecac6cc6db74675847e3f4ef29d9a25b7adc043567873 |
ISSN | 1078-0432 1557-3265 |
IngestDate | Thu Jul 10 19:02:20 EDT 2025 Thu Apr 03 07:01:44 EDT 2025 Thu Apr 24 23:09:21 EDT 2025 Tue Jul 01 03:06:42 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c375t-76602b51c7f77fac4dd8ecac6cc6db74675847e3f4ef29d9a25b7adc043567873 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 23340296 |
PQID | 1317850041 |
PQPubID | 23479 |
PageCount | 11 |
ParticipantIDs | proquest_miscellaneous_1317850041 pubmed_primary_23340296 crossref_citationtrail_10_1158_1078_0432_CCR_12_1959 crossref_primary_10_1158_1078_0432_CCR_12_1959 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2013-03-15 |
PublicationDateYYYYMMDD | 2013-03-15 |
PublicationDate_xml | – month: 03 year: 2013 text: 2013-03-15 day: 15 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Clinical cancer research |
PublicationTitleAlternate | Clin Cancer Res |
PublicationYear | 2013 |
References | Basu (2022061106492973200_bib21) 2003; 11 Chaffer (2022061106492973200_bib14) 2011; 331 Dykxhoorn (2022061106492973200_bib15) 2009; 4 Matallanas (2022061106492973200_bib31) 2007; 27 Shimono (2022061106492973200_bib10) 2009; 138 John (2022061106492973200_bib25) 2004; 2 Hu (2022061106492973200_bib40) 2009; 114 Grimson (2022061106492973200_bib24) 2007; 27 Ma (2022061106492973200_bib4) 2007; 449 Yuan (2022061106492973200_bib18) 2008; 15 Strano (2022061106492973200_bib32) 2001; 276 Schickel (2022061106492973200_bib7) 2010; 38 Dimmer (2022061106492973200_bib28) 2012; 40 Levy (2022061106492973200_bib19) 2008; 29 Gregory (2022061106492973200_bib23) 2008; 10 Simpson (2022061106492973200_bib35) 2008; 272 Berry (2022061106492973200_bib1) 2005; 353 Park (2022061106492973200_bib12) 2008; 22 Weigelt (2022061106492973200_bib3) 2005; 5 Cochrane (2022061106492973200_bib8) 2010; 2010 Eguiara (2022061106492973200_bib33) 2011; 10 Korpal (2022061106492973200_bib16) 2011; 17 Hurst (2022061106492973200_bib17) 2009; 69 Smoot (2022061106492973200_bib29) 2011; 27 Iliopoulos (2022061106492973200_bib9) 2010; 39 Rouhi (2022061106492973200_bib22) 2010; 5 Betel (2022061106492973200_bib26) 2008; 36 Tavazoie (2022061106492973200_bib5) 2008; 451 Oka (2022061106492973200_bib37) 2008; 283 Nam (2022061106492973200_bib41) 2008; 14 Maragkakis (2022061106492973200_bib27) 2009; 37 Eccles (2022061106492973200_bib2) 2007; 369 Huang (2022061106492973200_bib20) 2005; 122 Bracken (2022061106492973200_bib11) 2008; 68 Aqeilan (2022061106492973200_bib38) 2005; 65 Korpal (2022061106492973200_bib13) 2008; 283 Valastyan (2022061106492973200_bib6) 2009; 137 Hanahan (2022061106492973200_bib36) 2011; 144 Levy (2022061106492973200_bib30) 2006; 14 Chiarugi (2022061106492973200_bib39) 2008; 76 Burk (2022061106492973200_bib34) 2008; 9 |
References_xml | – volume: 38 start-page: 908 year: 2010 ident: 2022061106492973200_bib7 article-title: mir-200c regulates induction of apoptosis through CD95 by targeting FAP-1 publication-title: Mol Cell doi: 10.1016/j.molcel.2010.05.018 – volume: 5 start-page: 1911 year: 2010 ident: 2022061106492973200_bib22 article-title: Hypoxia-induced metastasis model in embryonic zebrafish publication-title: Nat Protoc doi: 10.1038/nprot.2010.150 – volume: 65 start-page: 6764 year: 2005 ident: 2022061106492973200_bib38 article-title: WW domain–containing proteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-05-1150 – volume: 76 start-page: 1352 year: 2008 ident: 2022061106492973200_bib39 article-title: Anoikis: a necessary death program for anchorage-dependent cells publication-title: Biochem Pharmacol doi: 10.1016/j.bcp.2008.07.023 – volume: 10 start-page: 3751 year: 2011 ident: 2022061106492973200_bib33 article-title: Xenografts in zebrafish embryos as a rapid functional assay for breast cancer stem-like cell identification publication-title: Cell Cycle doi: 10.4161/cc.10.21.17921 – volume: 11 start-page: 11 year: 2003 ident: 2022061106492973200_bib21 article-title: Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis publication-title: Mol Cell doi: 10.1016/S1097-2765(02)00776-1 – volume: 36 start-page: D149 year: 2008 ident: 2022061106492973200_bib26 article-title: The microRNA.org resource: targets and expression publication-title: Nucleic Acids Res doi: 10.1093/nar/gkm995 – volume: 276 start-page: 15164 year: 2001 ident: 2022061106492973200_bib32 article-title: Physical Interaction with Yes-associated protein enhances p73 transcriptional activity publication-title: J Biol Chem doi: 10.1074/jbc.M010484200 – volume: 14 start-page: 743 year: 2006 ident: 2022061106492973200_bib30 article-title: The Yes-associated protein 1 stabilizes p73 by preventing Itch-mediated ubiquitination of p73 publication-title: Cell Death Differ doi: 10.1038/sj.cdd.4402063 – volume: 283 start-page: 14910 year: 2008 ident: 2022061106492973200_bib13 article-title: The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2 publication-title: J Biol Chem doi: 10.1074/jbc.C800074200 – volume: 40 start-page: D565 year: 2012 ident: 2022061106492973200_bib28 article-title: The UniProt-GO annotation database in 2011 publication-title: Nucleic Acids Res doi: 10.1093/nar/gkr1048 – volume: 17 start-page: 1101 year: 2011 ident: 2022061106492973200_bib16 article-title: Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization publication-title: Nat Med doi: 10.1038/nm.2401 – volume: 272 start-page: 177 year: 2008 ident: 2022061106492973200_bib35 article-title: Anoikis resistance and tumor metastasis publication-title: Cancer Lett doi: 10.1016/j.canlet.2008.05.029 – volume: 2010 year: 2010 ident: 2022061106492973200_bib8 article-title: Loss of miR-200c: a marker of aggressiveness and chemoresistance in female reproductive cancers publication-title: J Oncol doi: 10.1155/2010/821717 – volume: 69 start-page: 7495 year: 2009 ident: 2022061106492973200_bib17 article-title: Metastamir: the field of metastasis-regulatory microRNA Is spreading publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-09-2111 – volume: 144 start-page: 646 year: 2011 ident: 2022061106492973200_bib36 article-title: Hallmarks of cancer: The next generation publication-title: Cell doi: 10.1016/j.cell.2011.02.013 – volume: 10 start-page: 593 year: 2008 ident: 2022061106492973200_bib23 article-title: The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1 publication-title: Nat Cell Biol doi: 10.1038/ncb1722 – volume: 14 start-page: 2690 year: 2008 ident: 2022061106492973200_bib41 article-title: MicroRNA expression profiles in serous ovarian carcinoma publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-07-1731 – volume: 137 start-page: 1032 year: 2009 ident: 2022061106492973200_bib6 article-title: A pleiotropically acting MicroRNA, miR-31, inhibits breast cancer metastasis publication-title: Cell doi: 10.1016/j.cell.2009.03.047 – volume: 27 start-page: 962 year: 2007 ident: 2022061106492973200_bib31 article-title: RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein publication-title: Mol Cell doi: 10.1016/j.molcel.2007.08.008 – volume: 449 start-page: 682 year: 2007 ident: 2022061106492973200_bib4 article-title: Tumour invasion and metastasis initiated by microRNA-10b in breast cancer publication-title: Nature doi: 10.1038/nature06174 – volume: 451 start-page: 147 year: 2008 ident: 2022061106492973200_bib5 article-title: Endogenous human microRNAs that suppress breast cancer metastasis publication-title: Nature doi: 10.1038/nature06487 – volume: 138 start-page: 592 year: 2009 ident: 2022061106492973200_bib10 article-title: Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells publication-title: Cell doi: 10.1016/j.cell.2009.07.011 – volume: 122 start-page: 421 year: 2005 ident: 2022061106492973200_bib20 article-title: The hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating yorkie, the drosophila homolog of yap publication-title: Cell doi: 10.1016/j.cell.2005.06.007 – volume: 283 start-page: 27534 year: 2008 ident: 2022061106492973200_bib37 article-title: Mst2 and Lats kinases regulate apoptotic function of Yes kinase-associated protein (YAP) publication-title: J Biol Chem doi: 10.1074/jbc.M804380200 – volume: 27 start-page: 91 year: 2007 ident: 2022061106492973200_bib24 article-title: MicroRNA targeting specificity in mammals: determinants beyond seed pairing publication-title: Mol Cell doi: 10.1016/j.molcel.2007.06.017 – volume: 68 start-page: 7846 year: 2008 ident: 2022061106492973200_bib11 article-title: A Double-Negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-08-1942 – volume: 29 start-page: 350 year: 2008 ident: 2022061106492973200_bib19 article-title: Yap1 phosphorylation by c-Abl is a critical step in selective activation of proapoptotic genes in response to DNA damage publication-title: Mol Cell doi: 10.1016/j.molcel.2007.12.022 – volume: 5 start-page: 591 year: 2005 ident: 2022061106492973200_bib3 article-title: Breast cancer metastasis: markers and models publication-title: Nat Rev Cancer doi: 10.1038/nrc1670 – volume: 331 start-page: 1559 year: 2011 ident: 2022061106492973200_bib14 article-title: A perspective on cancer cell metastasis publication-title: Science doi: 10.1126/science.1203543 – volume: 22 start-page: 894 year: 2008 ident: 2022061106492973200_bib12 article-title: The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2 publication-title: Gen Dev doi: 10.1101/gad.1640608 – volume: 353 start-page: 1784 year: 2005 ident: 2022061106492973200_bib1 article-title: Effect of screening and adjuvant therapy on mortality from breast cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa050518 – volume: 39 start-page: 761 year: 2010 ident: 2022061106492973200_bib9 article-title: Loss of miR-200 inhibition of Suz12 leads to Polycomb-mediated repression required for the formation and maintenance of cancer stem cells publication-title: Mol Cell doi: 10.1016/j.molcel.2010.08.013 – volume: 15 start-page: 1752 year: 2008 ident: 2022061106492973200_bib18 article-title: Yes-associated protein (YAP) functions as a tumor suppressor in breast publication-title: Cell Death Differ doi: 10.1038/cdd.2008.108 – volume: 369 start-page: 1742 year: 2007 ident: 2022061106492973200_bib2 article-title: Metastasis: recent discoveries and novel treatment strategies publication-title: Lancet doi: 10.1016/S0140-6736(07)60781-8 – volume: 9 start-page: 582 year: 2008 ident: 2022061106492973200_bib34 article-title: A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells publication-title: EMBO Rep doi: 10.1038/embor.2008.74 – volume: 4 start-page: e7181 year: 2009 ident: 2022061106492973200_bib15 article-title: miR-200 enhances mouse breast cancer cell colonization to form distant metastases publication-title: PLoS One doi: 10.1371/journal.pone.0007181 – volume: 37 start-page: W273 year: 2009 ident: 2022061106492973200_bib27 article-title: DIANA-microT web server: elucidating microRNA functions through target prediction publication-title: Nucleic Acids Res doi: 10.1093/nar/gkp292 – volume: 2 start-page: e363 year: 2004 ident: 2022061106492973200_bib25 article-title: Human microRNA targets publication-title: PLoS Biol doi: 10.1371/journal.pbio.0020363 – volume: 27 start-page: 431 year: 2011 ident: 2022061106492973200_bib29 article-title: Cytoscape 2.8: new features for data integration and network visualization publication-title: Bioinformatics doi: 10.1093/bioinformatics/btq675 – volume: 114 start-page: 457 year: 2009 ident: 2022061106492973200_bib40 article-title: A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2009.05.022 |
SSID | ssj0014104 |
Score | 2.463941 |
Snippet | Purpose: The process of metastases involves the dissociation of cells from the primary tumor, penetration into the basement membrane, invasion, and exiting... The process of metastases involves the dissociation of cells from the primary tumor, penetration into the basement membrane, invasion, and exiting from the... |
SourceID | proquest pubmed crossref |
SourceType | Aggregation Database Index Database Enrichment Source |
StartPage | 1389 |
SubjectTerms | Adaptor Proteins, Signal Transducing - genetics Adaptor Proteins, Signal Transducing - metabolism Animals Anoikis - genetics Breast Neoplasms - genetics Breast Neoplasms - metabolism Breast Neoplasms - pathology Cell Movement - genetics Cell Proliferation Female Gene Expression Regulation, Neoplastic Humans MCF-7 Cells Mice MicroRNAs - genetics MicroRNAs - metabolism Neoplasm Metastasis Phosphoproteins - genetics Phosphoproteins - metabolism Transcription Factors |
Title | MicroRNA-200a Promotes Anoikis Resistance and Metastasis by Targeting YAP1 in Human Breast Cancer |
URI | https://www.ncbi.nlm.nih.gov/pubmed/23340296 https://www.proquest.com/docview/1317850041 |
Volume | 19 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Li9swEBbtFkovpe-mL1TobXEay5IfxxB2SdMkLUsCyUnIkgyB1ild57D99Z2RZCeBlG57MYmMLDPzMZ73EPIhrniVC60jwIYCA6UwUV4IFtm4xC-MUbHzd8zm6XjJJytxEGh31SVN2de_TtaV_A9XYQ34ilWy_8DZ7qGwAL-Bv3AFDsP1VjyeYTbd1XyIr6sw1QrobrHp8nYDeuE5WNKoHbY1Ad9to-AvdiBBndOlgKOjYD38GqPbw4_rKzFLvcFkMB0Sd9s-Bm0Npb91HtoEde7k9c57mOtocgC5sVudwDnRuv1KushR8FOvNuroxnTnQ0HwiGgWuoIHpwQOiEgiX5bZylEBsov5MRB9e2KtFb7FAcgOJSkGUE-LeJE7bwN2BuYJ649GV5hegk1y9t-0No4__yIvl9OpXFysFnfJPQa2hLO7P33uQk08djMmu7cLZV5wzMeThxwrMH-wSpx2snhEHgazgg49Rh6TO7Z-Qu7PQuLEU6KOoEJbqNAAFbqHCiwZuocKLW9oBxWKUKGbmjqoUA8V6vHwjCwvLxajcRSma0Q6yUQTZWk6YKWIdVZlWaU0Nya3WulU69SUOIUGI-g2qbitWGEKxUSZKaOBHgI0nCx5Ts7qbW1fEmrAKEiUBZYNci4UKwaGpUmiOcgHoVPbI7wlmdSh9TxOQPkmnQkqcomUlkhpCZSWMZNI6R7pd9t--N4rf9vwvuWHBCmJoS9V2-3uWsagJucCm8v1yAvPqO6RLEn4gBXpq1vsfk0e7OH-hpw1P3f2LWilTfnOoeo3DRWGvw |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=MicroRNA-200a+promotes+anoikis+resistance+and+metastasis+by+targeting+YAP1+in+human+breast+cancer&rft.jtitle=Clinical+cancer+research&rft.au=Yu%2C+San-Jian&rft.au=Hu%2C+Jing-Ying&rft.au=Kuang%2C+Xia-Ying&rft.au=Luo%2C+Jian-Min&rft.date=2013-03-15&rft.issn=1557-3265&rft.eissn=1557-3265&rft.volume=19&rft.issue=6&rft.spage=1389&rft_id=info:doi/10.1158%2F1078-0432.CCR-12-1959&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1078-0432&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1078-0432&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1078-0432&client=summon |